- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06022224
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELLVACCINE TRIAL
A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of a 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELLVACCINE TRIAL
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Newport Beach, California, United States, 92663
- Hoag Memorial Hospital Presbyterian
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
Male or female participants ≥16 years of age, at randomization.
• Refer to Appendix 2 for reproductive criteria for male and female participants.
Type of Participant and Disease Characteristics:
- Participants who are willing and able to comply with all scheduled assessments, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for Phase 3 participants with known stable infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) can be found in Appendix 3.
Participants who, in the judgment of the investigator, are at higher risk for SARS-CoV-2 infection and subsequent development of COVID-19 (including, but not limited to, use of mass transportation, relevant demographics, and frontline essential workers).
Informed Consent:
- Capable of giving personal signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Phase 2 only: Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
- Receipt of medications intended to prevent COVID-19.
- Previous clinical or microbiological diagnosis of COVID-19.
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate subcutaneous injection.
Women who are pregnant or breastfeeding.
Prior/Concomitant Therapy:
- Previous vaccination with any coronavirus vaccine.
- Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.
Prior/Concurrent Clinical Study Experience:
- Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. Other Exclusions
- Investigator site staff or Sponsor employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hAd5-S-Fusion+N-ETSD
Prime (SC, Day 1) + Boost (SC, Day 22) @ 1x10^11 VP/dose
|
Clear and colorless liquid.
Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10^11 viral particles/mL.
|
Placebo Comparator: Placebo
Prime (SC, Day 1) + Boost (SC, Day 22)
|
Clear and colorless liquid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
COVID-19 incidence based on central laboratory or locally confirmed nucleic acid amplification test (NAAT) in subjects with no serological or virological evidence (up to 14 days after receipt of the last dose) of past SARS-CoV-2 infection
Time Frame: 14 days after receipt of the last dose
|
To evaluate the efficacy of prophylactic hAd5-SFusion+ N-ETSD against confirmed COVID-19 in subjects without serological or virological evidence of infection before vaccination
|
14 days after receipt of the last dose
|
COVID-19 incidence based on central laboratory or locally confirmed NAAT in subjects with and without serological or virological evidence of infection before vaccination
Time Frame: Before vaccination
|
To evaluate the efficacy of prophylactic hAd5-SFusion+ N-ETSD against confirmed COVID-19 in subjects with and without serological or virological evidence of infection before vaccination
|
Before vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmed NAAT severe COVID-19 incidence in subjects with no serological or virological evidence of past SARS-CoV-2 infection
Time Frame: Before vaccination
|
To evaluate the efficacy of prophylactic hAd5-SFusion+ N-ETSD against confirmed severe COVID-19 in subjects without serological or virological evidence of infection before vaccination
|
Before vaccination
|
Confirmed NAAT severe COVID-19 incidence in subjects with and without serological or virological evidence of infection before vaccination
Time Frame: Before vaccination
|
To evaluate the efficacy of prophylactic hAd5-SFusion+N-ETSD against confirmed severe COVID-19 in subjects with and without serological or virological evidence of infection before vaccination
|
Before vaccination
|
COVID-19 incidence based on central laboratory or locally confirmed (according to the CDC-defined symptoms) in subjects with no serological or virological evidence (up to 14 days after receipt of the last dose) of past SARS-CoV-2 infection
Time Frame: 14 days after receipt of the last dose
|
To describe the efficacy of prophylactic hAd5-SFusion+N-ETSD against confirmed COVID-19 (according to the CDC defined symptoms) in subjects without serological or virological evidence of infection before vaccination
|
14 days after receipt of the last dose
|
COVID-19 incidence based on central laboratory or locally confirmed (according to the CDC-defined symptoms) in subjects with and without serological or virological evidence of infection before vaccination
Time Frame: Before vaccination
|
To describe the efficacy of prophylactic hAd5-SFusion+N-ETSD against confirmed COVID-19 (according to the CDCdefined symptoms) in subjects with and without serological or virological evidence of infection before vaccination
|
Before vaccination
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COVID-3.001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on hAd5-S-Fusion+N-ETSD
-
ImmunityBio, Inc.Unknown
-
ImmunityBio, Inc.Active, not recruiting
-
ImmunityBio, Inc.Completed
-
ImmunityBio, Inc.Withdrawn
-
ImmunityBio, Inc.Not yet recruitingHPV-Related Carcinoma
-
Queen's UniversityUnknown
-
Aguiflai Iberica, S.L.Completed
-
Vertebral Technologies, Inc.UnknownBack Pain | ScoliosisUnited States
-
Seoul National University HospitalCompletedLiver Fibroses | Liver MassKorea, Republic of